Therapy of anemia in kidney failure, using plasmid encoding erythropoietin.


Numerous studies using erythropoietin (EPO) gene delivery vectors, either viral or nonviral, have shown uncontrolled EPO expression leading to transient or sustained erythrocytosis and, more recently, severe autoimmune anemia. Therefore, there is a need to develop other EPO gene delivery systems that allow sustained and adjustable expression of EPO. We have… (More)
DOI: 10.1089/hum.2006.0101


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics